Editorial: first among Equals-not for either infliximab or adalimumab in Crohn's disease-yet

Aliment Pharmacol Ther. 2018 Apr;47(8):1225-1226. doi: 10.1111/apt.14549.

Authors

M H Lim¹, J D Doecke², G L Radford-Smith^{1

3

4}

Affiliations

¹ Department of Gastroenterology & Hepatology, Royal Brisbane and Women's Hospital, Brisbane, Australia.
² CSIRO Health and Biosecurity/Australian e-Health Research Centre, Brisbane, Australia.
³ IBD Research group, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
⁴ University of Queensland School of Medicine, Brisbane, Australia.

PMID: 29574876
DOI: 10.1111/apt.14549

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Adalimumab
Anti-Inflammatory Agents
Antibodies, Monoclonal
Biological Products*
Cohort Studies
Crohn Disease*
Denmark
Humans
Infliximab

Substances

Anti-Inflammatory Agents
Antibodies, Monoclonal
Biological Products
Infliximab
Adalimumab